TABLE 2.

Pre‐ablation model for NTR (competing‐risk regression)

Variables	Univariate analysis		Multivariate analysis		Bootstrapping (200 replications)
	SHR (95% CI)	p	SHR (95% CI)	p	SHR (95% CI)	p
Patients
Age (>65 vs. ≤65 years)	0.48 (0.21–1.11)	0.08
Sex (female vs. male)	0.85 (0.37–1.97)	0.70
BMI (≥30 vs. <30)	1.4 (0.66–2.97)	0.38
ASA (>2 vs. ≤2)	0.84 (0.45–1.56)	0.45
Diabetes	1.19 (0.62–2.29)	0.59
Metformin treatment	0.70 (0.27–1.79)	0.46
Statin treatment	0.85 (0.33–2.17)	0.74
Non‐HCC naive	3 (1.54–5.85)	0.001	3.77 (1.64–8.64)	0.002	3.77 (1.38–10.31)	0.010
Cirrhosis	1.32 (0.33–5.16)	0.68
Steatosis	0.79 (0.40–1.56)	0.51
Child‐Pugh (B vs. A)	0.97 (0.10–8.91)	0.98
Cause of liver disease (vs. alcohol)
Viral hepatitis	1.09 (0.54–2.23)	0.801
Other	0.14 (0.2–1.02)	0.059
Laboratory data
AFP (≥100 vs. <100 ng/ml)	6.35 (2.67–15.11)	<0.001	7.28 (2.63–20.14)	<0.001	7.28 (1.78–29.79)	0.006
Prothrombin time	0.99 (0.97–1.02)	0.77
Platelet count (≥100 vs. <100 ×10/mm3)	1.08 (0.52–2.26)	0.83
Albumin	0.98 (0.92–1.04)	0.53
Bilirubin	1.01 (0.96–1.06)	0.64
Neutrophils	0.91 (0.72–1.15)	0.46
Lymphocytes	0.81 (0.6–1.11)	0.2
Monocytes	0.73 (0.24–2.18)	0.58
MELD (>9 vs. ≤9)	1.03 (0.52–2.03)	0.92
ALBI score (2 vs. 1)	0.92 (0.47–1.80)	0.81
HCC
Multifocal (vs. unifocal)	2.07 (1.08–3.94)	0.027	1.67 (0.75–3.71)	0.20	1.67 (0.64–4.38)	0.64
Tumor size (<2 vs. ≥2 cm)	1.26 (0.57–2.78)	0.56
Steatotic HCC	0.3 (0.09–0.96)	0.044	0.54 (0.157–1.88)	0.335	0.54 (0–196.11)	0.84
Subcapsular location	1.21 (0.64–2.29)	0.54
PTA
Modality (MW vs. RF)	1.9 (0.97–3.67)	0.07
Guidance (US vs. CT)	1.46 (0.78–2.75)	0.24
Harrell's C statistic: 0.76

Abbreviations: SHR, subdistribution hazard ratio; CI, confidence interval.

Data in bold are statistically significant (i.e., p < 0.05).